Abstract:RNAs with 5′‐triphosphate (ppp) are detected in the cytoplasm principally by the innate immune receptor RIG‐I, whose activation triggers a Type I interferon response. Cellular RNAs undergo post‐transcriptional modifications which ensures that self RNAs do not carry 5′ppp and/or blunt‐ends. We carried out a thorough biochemical characterization of RIG‐I complexes with RNAs carrying various end‐modifications as well as measured the effect of these end‐modifications on their signaling activity. We find that discrimination of RNA ligands occurs at multiple stages and signaling RNAs have high affinity and ATPase turnover rate and thus a high k atpase / K d . Our studies reveal that the autoinhibitory interface between CARD2 (second CARD) and Hel2i (Helicase 2 insertion domain) plays a critical role in RNA selectivity, wherein this interface acts as a “gate” that prevents cellular RNAs from generating productive complexes that can signal. It is thought that self RNAs like mRNAs are not recognized by RIG‐I because 5′ppp is capped by the addition of a 7‐methyl guanosine (m7G) (Cap‐0) and the 5′‐end nucleotide ribose is 2′‐O‐methylated (Cap‐1). We provide a structural and mechanistic basis for the exact roles of capping and 2′‐O‐methylation in evading RIG‐I recognition using enzymatic assays, X‐ray crystallography and cell‐based signaling studies. Surprisingly, we find that Cap‐0 and 5′ppp dsRNA have similar binding affinities, activate RIG‐I's ATPase to the same extent, and shows the same cellular signaling response. Three new crystal structures of RIG‐I complexes with dsRNA bearing 5′OH, 5′ppp, and 5′Cap‐0 reveal that RIG‐I accommodates m7G in a cavity created through conformational changes in helicase‐motif IVa without perturbing the triphosphate interactions. In contrast, Cap‐1 modifications abrogate RIG‐I signaling through a mechanism involving the H830 residue, wherein 2′‐O‐methylation works synergistically with m7G capping to weaken RNA affinity and ATPase activity. Our work provides new structural insights into the host and viral immune evasive mechanisms from RIG‐I explaining the complexity of cap structures over evolution. Support or Funding Information This work was supported by NIH grant GM111959 to Joseph Marcotrigiano and Smita S Patel.

The molecular mechanism of RIG‐I activation and signaling

Host and Viral Modulation of RIG-I-Mediated Antiviral Immunity

RIG-I in RNA virus recognition

Structural and biochemical studies of RIG-I antiviral signaling

Pattern Recognition and Signaling Mechanisms of RIG-I and MDA5

Structural basis of RNA recognition and activation by innate immune receptor RIG-I

Structures of RIG-I-Like Receptors and Insights into Viral RNA Sensing.

Retinoic acid inducible gene-I, more than a virus sensor

Structural and Functional Insights into 5′-Ppp RNA Pattern Recognition by the Innate Immune Receptor RIG-I

Structural and Mechanistic Basis for Self Versus Non‐self RNA Discrimination by the Innate Immune Receptor RIG‐I

The structural basis of 5' triphosphate double-stranded RNA recognition by RIG-I C-terminal domain.

RIG-I-like receptors: their regulation and roles in RNA sensing

RIG-I-like receptor DRH-1 signals via CARDs to activate anti-viral immunity in intestinal cells

Master sensors of pathogenic RNA - RIG-I like receptors

The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses

Activation of innate immune defense mechanisms by signaling through RIG-I/IPS-1 in intestinal epithelial cells

Actin cytoskeleton remodeling primes RIG-I-like receptor activation

Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors

Helicase protein DDX11 as a novel antiviral factor promoting RIG-I-MAVS-mediated signaling pathway

Agonist and Antagonist Recognition by Rig-I, A Cytoplasmic Innate Immunity Receptor

A Hierarchical Mechanism of RIG-I Ubiquitination Provides Sensitivity, Robustness and Synergy in Antiviral Immune Responses